The CTS™ DynaMag™ Magnet is suitable for use with commercially available sterile blood/culture bags, tubing, and connectors.Benefits:• Ideal for magnetic詳細を見る
The CTS™ DynaMag™ Magnet is suitable for use with commercially available sterile blood/culture bags, tubing, and connectors.
Benefits: • Ideal for magnetic isolation in closed, sterile blood bags • Scalable volumes: 50 to 330 mL in static separations and >10 L in continuous flow separations following T-cell expansion protocols • Residual beads that escape initial magnetic capture are retained on a secondary magnet
Applications: • Positive isolation of CD3+ T-cells for subsequent stimulation/expansion with CTS™ Dynabeads™ CD3/CD28 and removal of CTS Dynabeads CD3/CD28 following T-cell expansion
The CTS DynaMag Magnet is intended for use with the CTS Dynabeads product portfolio in clinical research such as CTS Dynabeads CD3/CD28 (Cat. No. 40203D).
Do not submerge the magnet unit in aqueous solutions and avoid prolonged exposure to water or aqueous solutions. Clean with a damp cloth and mild detergent when exposed to harsh solvents. Do not autoclave the magnet unit as heating the magnet to above 70 degrees C can destabilize the magnetic material, resulting in loss of magnetic strength.
What is the difference between the DynaMag-2 Magnet (Cat. No. 12321D) and DynaMag-Spin Magnet (Cat. No. 12320D)?
The DynaMag-2 Magnet can hold 16 standard 1.5 mL or 2 mL microcentrifuge tubes, while the DynaMag-Spin Magnet holds up to 6 standard 1.5 mL microcentrifuge tubes.
What is the definition of superparamagnetic, and what does this mean for my cell isolation application with Dynabeads magnetic beads?
Superparamagnetic means that the Dynabeads magnetic beads exhibit magnetic properties when placed within a magnetic field, but have no residual magnetism when removed from the magnetic field.
This means that your targeted cells, proteins, or nucleic acids are only subjected to magnetic forces during the time the beads are on the magnet. The beads do not aggregate, but remain evenly dispersed in suspension.
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Authors:Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I,
Journal:J Immunother
PubMed ID:19238016
On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. We present here the validation of ... More
Simplified process for the production of anti-CD19-CAR-engineered T cells.
Authors:Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, Wayne A, Sabatino M,
Journal:
PubMed ID:23992830
Adoptive immunotherapy with the use of chimeric antigen receptor (CAR)-engineered T cells specific for CD19 has shown promising results for the treatment of B-cell lymphomas and leukemia. This therapy involves the transduction of autologous T cells with a viral vector and the subsequent cell expansion. We describe a new, simplified ... More